Other medications, like GLP-1 receptor agonists (e.g., semaglutide), slow stomach emptying and affect satiety hormones, so the approach can vary depending on the drug
[PMID: 9497180] PubMed record related to this compound for laboratory literature review
Previous meta-analyses have indicated that tirzepatide might potentially decrease the risk of cardiovascular events by affecting cardiac cells, the pancreas, and other tissues directly and indirectly [2]
[PMID: 12526981] PubMed record related to this compound for laboratory literature review
For a complete side-by-side receptor comparison covering when to select MT-1 versus MT-2 and what each receptor subtype contributes to the data, see the MT-1 10mg research guide and MT-2 10mg research guide on the Ascend Peptides UK blog
GLP-1RA vs DPP-4i use and rates of hyperkalemia and RAS blockade discontinuation in type 2 diabetes